Researchers Warn Oral Food Challenges May Slow Food Allergy Research Progress

As food allergy treatments continue to expand beyond simple avoidance strategies, researchers are warning that the oral food challenge (OFC)—long considered the gold standard for diagnosis—is becoming a major obstacle to future clinical trials. Experts say the burdens, risks, and logistical demands associated with OFCs may now be slowing research progress and limiting patient participation.

Oral immunotherapy (OIT), which involves gradually consuming small amounts of an allergen under medical supervision, has emerged as a promising way to reduce the risk of severe reactions from accidental exposure. However, in an article published in the journal Allergy, researchers note that proving a therapy works still often depends on oral food challenges, where patients intentionally consume allergens in a clinical setting to measure their reaction threshold.

While OFCs remain one of the most reliable ways to confirm food allergy outcomes, they carry significant risks and practical challenges. Participants may experience allergic symptoms ranging from mild itching and stomach discomfort to severe reactions requiring emergency treatment. Researchers emphasized that these procedures can be emotionally stressful for families and require extensive specialist oversight.

The burden associated with food challenges can also discourage participation in clinical trials. Patients often face repeated clinic visits, long observation periods, missed school or work, and concerns about triggering dangerous reactions. Experts warn that these barriers may reduce enrollment and limit diversity in studies, making it harder to evaluate how treatments perform across broader patient populations.

The researchers say patient selection and safety monitoring remain critical throughout both food challenges and OIT programs. Individuals with poorly controlled asthma or a history of severe reactions may face higher risks during testing and treatment, requiring careful evaluation before participation.

Another challenge involves measuring long-term success. Many patients undergoing OIT achieve desensitization, meaning they can tolerate an allergen while maintaining regular exposure. However, sustained tolerance after stopping treatment remains less predictable, and scientists are still working to understand why some patients maintain protection while others lose it over time.

To address these concerns, researchers are exploring alternatives that could reduce reliance on traditional oral food challenges. Potential strategies include improved biomarkers, diagnostic algorithms, and modified trial designs that lessen patient burden while still providing reliable scientific data. Experts say future progress in food allergy treatment will depend not only on developing new therapies, but also on creating safer and more practical ways to evaluate them.